placebo over 52 weeks Efficacy observed both as monotherapy or combined with antifibrotics Well-tolerated, reduced death risk, though did not show statistically significant survival benefit Why it matters: Anti-inflammatory mechanism differentiates JASCAYD from existing antifibrotics (nintedanib, pirfenidone) Reinforces Boehringers leadership in respiratory innovation and re-energizes IPF R&D after years of limited breakthroughs Follow our page for more such updates: News Source: #FDAApproval #IPF #PulmonaryFibrosis #Respiratory #RespiratoryMedicine #DrugDevelopment #BoehringerIngelheim #Ofev #Esbriet #PharmaInnovation To view or add a comment, sign in This milestone marks a major advance for patients with progressive fibrotic lung disease, expanding treatment options beyond current antifibrotics
The trial included a 24-week extension period at doses of 9 or 12 mg for about 500 adults with a BMI of 35 or greater, which is classified as severe obesity
The Healing Peptide (BPC-157 Therapy) is a synthetic peptide derived from a protein found in the stomach, known for its healing and anti-inflammatory properties
Ignors, ils peuvent mener des maladies chroniques, qui ont augment de plus de 73 % ces dix dernires annes
Smnbrist pverkar ocks stressniver, vilket kan frstrka sug och gra det svrare att reglera knslotande
